TREATMENT OF SKIN DISEASES Russian patent published in 2025 - IPC A61K38/48 A61K8/64 A61K8/66 A61P17/00 A61Q19/08 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions refers to pharmacy and medicine, namely to treatment of skin diseases with clostridial neurotoxins. Method of treating a skin disease, comprising the intradermal administration of a botulinum neurotoxin in a therapeutically effective amount, where, after administration, the botulinum neurotoxin causes the secretion of one or more sebaceous lipids selected from squalene, a fatty acid, cholesterol and a wax ester in the epidermal layer of the skin, wherein the skin disease is a disease associated with a low level of one or more sebaceous lipids in the epidermal layer of the patient's skin compared to the level of one or more sebaceous lipids in a subject who does not have said skin disease. Non-therapeutic use of botulinum neurotoxin in an amount effective for cosmetic skin treatment, where the botulinum neurotoxin causes the secretion of one or more sebaceous lipids selected from squalene, fatty acid, cholesterol and wax ester, in the epidermal layer of the skin, where the botulinum neurotoxin is administered to a patient with sebum, which includes: fatty acid in a concentration of less than 50% vol./vol., a wax ester in a concentration of less than 20% vol./vol., squalene in a concentration of less than 10% vol./vol.; and / or cholesterol in a concentration of less than 4% vol./vol. Non-therapeutic use of botulinum neurotoxin in an amount effective to stimulate skin rejuvenation in a subject, where the botulinum neurotoxin causes the secretion of one or more sebaceous lipids selected from squalene, a fatty acid, cholesterol and a wax ester, in the epidermal layer of the skin, where the botulinum neurotoxin is administered to a patient having sebum, which includes: a fatty acid in a concentration of less than 50% vol./vol., complex wax ester in concentration of less than 20% vol./vol., squalene in concentration of less than 10% vol./vol.; and/or cholesterol in a concentration of less than 4% vol./vol.

EFFECT: declared group of inventions provides an increase in the levels of important protective sebaceous lipids in the sebum of the epidermis and improved quality of the sebum, as a result of which sebum contains a higher relative percentage of required lipids with intradermal administration of Clostridial neurotoxin.

75 cl, 17 dwg, 17 tbl, 16 ex